الفهرس 
Hepatitis C virusOnly 14 pages are availabe for public view
 |  | from | 94 |  |  |
| | | from | 94 | | |
Abstract
Egypt has the highest prevalence of antibodies to hepatitis C virus (HCV) in the world, estimated nationally at 14.7%. There are over 500,000 new infected persons per year by hepatitis C virus.
More than 90 % of Egyptian patients are infected with genotype IV.
Liver mortality in Egypt reaches 40,000 per year, making 10% of total mortality, and comes second after heart diseases.
The goal of antiviral therapy is to cure hepatitis C via a sustained elimination of the virus. Importantly, long-term benefits of sustained virological response (SVR) are the reduction of HCV-related hepatocellular carcinoma and overall mortality.
The development of new direct acting anti-viral for the treatment of chronic hepatitis C patients give us and the patients a new hope for cure from that disease and its complication.
Our study which was conducted in the national hepatology and tropical medicine research institute (NHTMRI) on 1000 Egyptian patients who were eligible to be treated with Sofosbuvir, Interferon and ribavirin or Sofosbuvir and ribavirin only.
All the included patients received Pegylated Interferon 180 mcg SC injection once / week, Weight-based RBV (1000 mg [<75 kg] to 1200 mg [≥75 kg]) oral capsule divided every 8 hours and sofosbuvir (400 mg) oral capsule every 24 hours for 12 weeks or Weight-based RBV (1000 mg [<75 kg] to 1200 mg [≥75 kg]) oral capsule divided every 8 hours and sofosbuvir (400 mg) oral capsule every 24 hours for 24 weeks.
The enrolled patients were divided into two groups, 500 patients who received dual therapy and 500 patients who received triple therapy.
We started with 1000 patients, 3 patients were excluded due to discontinuation of the therapy, 2 of them developed ascites, one stopped the therapy after development of hepatocellular carcinoma.
736 patients were males while 262 patients were females.
Regarding the degree of fibrosis which had been assessed fibroscan. there were 307 patients had fibrosis (F3) , 36 patients were in stage (F3-F4) and 509 patients were in the stage (F4) of fibrosis .
The mean age of the study group was 51.91+9.46years, the mean BMI of the study group was 33.26+25.95 kg/m2 , the mean AFP of the study 13.96+ 26.89 ng /ml , the mean HCV PCR of the study group before starting treatment 2897376.42+ 13539932.85
Regarding the PCR at end of treatment it was noted that all the patients (100 %) achieved viral clearance by the end of treatment in group of dual therapy and nearly all patients (99.2%) achieved viral clearance by the end of treatment in group of triple therapy.
Among cirrhotic patients, SVR 12 rates were 73.3% in dual group and 81.3% in triple group.
SVR 12 in treatment naïve patients received dual therapy was 78% while SVR 12 in treatment experienced patients received dual therapy was 72%. As regard group of patients received triple thepapy it was 83% and 76% respectively.
As regard the correlation between achieving sustained virological response (SVR 12) and the viral load before treatment, age, sex, BMI and years of HCV positivity. There is no statistical significance between any of them. Among cirrhotic patients, SVR 12 rates were 73.3% and 81.3% in group a and group b respectively.